PL2496225T3 - Inhibitory sfingozyny typu I oraz sposoby ich wytwarzania i zastosowania - Google Patents

Inhibitory sfingozyny typu I oraz sposoby ich wytwarzania i zastosowania

Info

Publication number
PL2496225T3
PL2496225T3 PL10757646T PL10757646T PL2496225T3 PL 2496225 T3 PL2496225 T3 PL 2496225T3 PL 10757646 T PL10757646 T PL 10757646T PL 10757646 T PL10757646 T PL 10757646T PL 2496225 T3 PL2496225 T3 PL 2496225T3
Authority
PL
Poland
Prior art keywords
inhibitors
making
methods
same
sphingosine
Prior art date
Application number
PL10757646T
Other languages
English (en)
Inventor
Robert Elliot Zipkin
Jeffrey Kroll Adams
Sarah Spiegel
Original Assignee
Enzo Therapeutics, Inc.
Virginia Commonwealth University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enzo Therapeutics, Inc., Virginia Commonwealth University filed Critical Enzo Therapeutics, Inc.
Publication of PL2496225T3 publication Critical patent/PL2496225T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/22Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
    • C07C215/28Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/64Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • C07C233/01Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/18Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/31Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/32Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton having at least one of the nitrogen atoms bound to an acyclic carbon atom of the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/04Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D263/06Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by oxygen atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/092Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings with aromatic radicals attached to the chain

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL10757646T 2009-08-31 2010-08-31 Inhibitory sfingozyny typu I oraz sposoby ich wytwarzania i zastosowania PL2496225T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/584,131 US8314151B2 (en) 2008-04-29 2009-08-31 Sphingosine kinase type 1 inhibitors, and processes for using same
EP10757646.4A EP2496225B1 (en) 2009-08-31 2010-08-31 Sphingosine type 1 inhibitors and methods for making and using same
PCT/US2010/002383 WO2011025545A1 (en) 2009-08-31 2010-08-31 Sphingosine type 1 inhibitors and methods for making and using same

Publications (1)

Publication Number Publication Date
PL2496225T3 true PL2496225T3 (pl) 2019-09-30

Family

ID=43030496

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10757646T PL2496225T3 (pl) 2009-08-31 2010-08-31 Inhibitory sfingozyny typu I oraz sposoby ich wytwarzania i zastosowania

Country Status (9)

Country Link
US (8) US8314151B2 (pl)
EP (2) EP2496225B1 (pl)
CA (1) CA2793090C (pl)
DK (1) DK2496225T3 (pl)
ES (1) ES2718091T3 (pl)
HU (1) HUE042907T2 (pl)
PL (1) PL2496225T3 (pl)
PT (1) PT2496225T (pl)
WO (1) WO2011025545A1 (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8314151B2 (en) 2008-04-29 2012-11-20 Enzo Therapeutics, Inc. Sphingosine kinase type 1 inhibitors, and processes for using same
WO2013003815A2 (en) * 2011-06-29 2013-01-03 The Oregon State Board Of Higher Education On Behalf Of Portland State University Near-infrared fluorescent dyes with large stokes shifts
WO2013071061A1 (en) * 2011-11-11 2013-05-16 The Children's Hospital Of Philadelphia Compositions and methods for increasing stress resilience
CA3061201A1 (en) 2017-06-23 2018-12-27 Enzo Biochem, Inc. Sphingosine pathway modulating compounds for the treatment of cancers
US10660879B2 (en) 2017-06-23 2020-05-26 Enzo Biochem, Inc. Sphingosine pathway modulating compounds for the treatment of cancers
US10364211B1 (en) * 2017-10-25 2019-07-30 Enzo Biochem, Inc. Methods and intermediates for synthesizing SK1-I
WO2020005313A1 (en) 2018-06-25 2020-01-02 Enzo Biochem, Inc. Sphingosine pathway modulating compounds for the treatment of cancers
EP4121025A4 (en) * 2020-03-17 2024-03-27 Enzo Biochem, Inc. Sphingosine pathway modulating compounds for the treatment of coronavirus infection
GB2617070B (en) * 2022-03-28 2024-08-14 Jaguar Land Rover Ltd Vehicle charging control system and method

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2868844A (en) 1957-01-22 1959-01-13 Ethyl Corp Selective nitration process
US3871958A (en) 1972-03-04 1975-03-18 Ajinomoto Kk Biological method of producing serine and serinol derivatives
US4707440A (en) * 1984-01-30 1987-11-17 Enzo Biochem, Inc. Nucleic acid hybridization assay and detectable molecules useful in such assay
US5948820A (en) * 1994-08-22 1999-09-07 Yoshitomi Pharmaceutical Industries, Ltd. Benzene compound and pharmaceutical use thereof
MXPA02009781A (es) 2000-04-03 2004-09-06 Sankyo Co Isoformas de esfingosina cinasa tipo 2 de mamifero, clonacion, expresion y metodos de uso de las mismas.
US20100056762A1 (en) * 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
WO2004080960A2 (en) * 2003-03-06 2004-09-23 Neose Technologies Inc. Methods and compositions for the enzymatic synthesis of gangliosides
AU2005249566B2 (en) 2004-06-04 2010-11-11 Genentech, Inc. Method for treating multiple sclerosis
KR20060002290A (ko) * 2004-07-01 2006-01-09 주식회사 두산 신규 스핑고리피드 유도체 및 그를 함유하는 항암 조성물
US8324237B2 (en) * 2005-05-20 2012-12-04 Smith Charles D Methods for the treatment and prevention of inflammatory diseases
ES2528451T3 (es) * 2005-06-17 2015-02-10 Apogee Biothechnology Corporation Inhibidores de esfingosina cinasa
US8148338B2 (en) 2006-02-22 2012-04-03 Supratek Pharma Inc. Doxorubicin formulations for anti-cancer use
US20080145883A1 (en) * 2006-10-09 2008-06-19 Thomas Baumruker Biomarker in inflammatory diseases
US8372888B2 (en) * 2008-04-29 2013-02-12 Enzo Therapeutics, Inc. Sphingosine kinase type 1 inhibitors, compositions and processes for using same
US8314151B2 (en) * 2008-04-29 2012-11-20 Enzo Therapeutics, Inc. Sphingosine kinase type 1 inhibitors, and processes for using same

Also Published As

Publication number Publication date
ES2718091T3 (es) 2019-06-27
US20100278741A1 (en) 2010-11-04
US10166204B2 (en) 2019-01-01
HUE042907T2 (hu) 2019-07-29
US10945971B2 (en) 2021-03-16
EP2496225B1 (en) 2019-01-16
US20210177776A1 (en) 2021-06-17
US20180235907A1 (en) 2018-08-23
PT2496225T (pt) 2019-04-26
US20120237448A9 (en) 2012-09-20
US11737992B2 (en) 2023-08-29
US10624863B2 (en) 2020-04-21
US10456370B2 (en) 2019-10-29
US9388121B2 (en) 2016-07-12
EP3417854A1 (en) 2018-12-26
US20190111007A1 (en) 2019-04-18
WO2011025545A1 (en) 2011-03-03
US20130245321A1 (en) 2013-09-19
US20200197328A1 (en) 2020-06-25
DK2496225T3 (en) 2019-04-15
CA2793090C (en) 2015-03-24
EP2496225A1 (en) 2012-09-12
US9974758B2 (en) 2018-05-22
CA2793090A1 (en) 2011-03-03
US20200069611A1 (en) 2020-03-05
US20160317472A1 (en) 2016-11-03
US8314151B2 (en) 2012-11-20

Similar Documents

Publication Publication Date Title
HRP20190214T1 (hr) Pripravci i metode za liječenje purpure
EP2200977A4 (en) F1F0-ATPASE INHIBITOR AND ASSOCIATED METHODS
GB0803559D0 (en) Multiple path intererometer and method
IL214403A0 (en) Novelcell lines and methods
EP2334804A4 (en) COCULTURAL COMPOSITIONS AND METHODS
PL2496225T3 (pl) Inhibitory sfingozyny typu I oraz sposoby ich wytwarzania i zastosowania
ZA201205277B (en) Sphingosine kinase inhibitors
ZA201205237B (en) Sphingosine kinase inhibitors
EP2222314A4 (en) METHOD AND MEANS FOR OBTAINING BRONCHORELAXATION
PL2862478T3 (pl) Szczoteczka do zębów i technologia jej produkcji
GB0912468D0 (en) Composition and method
IL205248A0 (en) Compositions and methods for making androstenediones
ZA201204262B (en) Composition for improving brain function and method for improving brain function
TWI370107B (en) Novel methods for making and using halosilylgermanes
EP2294199A4 (en) COMPOSITIONS AND METHODS FOR ENHANCING PLANTS
EP2373286A4 (en) COMPOSITIONS AND METHODS FOR PROMOTING A RELAXATION STATUS
GB2462518B (en) In-line testing
ZA201102837B (en) Phosphodiestarase inhibitors
TWI372256B (en) Test apparature and test method
GB0916010D0 (en) JMJD2 demethylase inhibitors
GB0909380D0 (en) Method and use
GB0903348D0 (en) Compounds and methods relating thereto
GB0901667D0 (en) Composition and method
GB0814657D0 (en) Compsoitions and methods for maintaining lipid health
GB0811799D0 (en) Method and arrangement for profiling consumers